Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy

[1]  K Dane Wittrup,et al.  A modular IgG-scFv bispecific antibody topology. , 2010, Protein engineering, design & selection : PEDS.

[2]  Yin Duan,et al.  Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals. , 2010, Bioconjugate chemistry.

[3]  S. Canevari,et al.  (177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. , 2009, Nuclear medicine and biology.

[4]  J. Pagel,et al.  A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. , 2009, Blood.

[5]  Sui Shen,et al.  MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan , 2009, Journal of Nuclear Medicine.

[6]  W. Mcbride,et al.  Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma , 2009, Journal of Nuclear Medicine.

[7]  Martin G Pomper,et al.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.

[8]  Timothy J. Hoffman,et al.  In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems , 2007, Journal of Nuclear Medicine.

[9]  J. Frangioni,et al.  Production of Multimeric Prostate-Specific Membrane Antigen Small-Molecule Radiotracers Using a Solid-Phase 99mTc Preloading Strategy , 2007, Journal of Nuclear Medicine.

[10]  P. Champéroux,et al.  Cardiovascular Safety of Gadoterate Meglumine (Gd-DOTA) , 2007, Investigative radiology.

[11]  M. Eisenhut,et al.  DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  B. Keil,et al.  [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  John V Frangioni,et al.  An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. , 2006, Contrast media & molecular imaging.

[14]  J. Pagel,et al.  A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. , 2006, Cancer research.

[15]  D. Scheinberg,et al.  Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys , 2006 .

[16]  Jacques Barbet,et al.  Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  Eva Forssell-Aronsson,et al.  Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. , 2005, Cancer biotherapy & radiopharmaceuticals.

[18]  J. Bading,et al.  Integrin αβ3-Targeted Imaging of Lung Cancer , 2005 .

[19]  J. Barbet,et al.  Recent advances in pretargeted radioimmunotherapy. , 2005, Current medicinal chemistry.

[20]  B. Wessels,et al.  Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  Michael G Stabin,et al.  PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT , 2003, Health physics.

[22]  Damon L. Meyer,et al.  Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  W. Oyen,et al.  Pretargeted radioimmunotherapy of cancer: progress step by step. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Gary L Griffiths,et al.  A universal pretargeting system for cancer detection and therapy using bispecific antibody. , 2003, Cancer research.

[25]  D. Hyre,et al.  A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. , 2002, Bioconjugate chemistry.

[26]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  S. Jurisson,et al.  Current and potential therapeutic uses of lanthanide radioisotopes. , 2000, Cancer biotherapy & radiopharmaceuticals.

[28]  E. Gautherot,et al.  Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  P. Beaumier,et al.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Goris,et al.  Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  D Huglo,et al.  Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  David M. Goldenberg,et al.  Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations , 1998, European Journal of Nuclear Medicine.

[33]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[34]  B. Bonnemain,et al.  Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. , 1990, Investigative radiology.

[35]  C. Meares,et al.  Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  S. Larson,et al.  Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  Ryan Park,et al.  MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.